Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surovatamig in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
NCT06137118Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Primary completion
- Jan 2028
- Countries
- 13
01
Overview
A Phase 2 trial of surovatamig in B cell acute lymphoblastic leukemia (B-ALL), sponsored by AstraZeneca. Started Dec 2023; status: recruiting.
02
Drugs
surovatamig
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06137118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137118.